title: [The effect of sandostatin and 5-fluorouracil on apoptosis in breast cancer].
abstract: OBJECTIVE
  To investigate the effect of 5-FU plus sandostatin on apoptosis in breast cancer.
  
  
  METHODS
  Breast cancer samples from 16 patients were treated with 5-FU (10 microg/ml) and sandostatin (0.1 microg/ml) in vitro using the in situ terminal deoxynucleotidyl transferase assay (TDT) to detect apoptosis. The patients were female (mean age 54.4 years). In the 16 patients, 10 had positive estrogen receptor (ER) and positive progestogen receptor (PR), and the rest had negative ER and PR.
  
  
  RESULTS
  18 hours after addition of 5-FU, sandostatin and both, the apoptotic rate of tumor cells was (21.8 +/- 6.6)%, (14.3 +/- 8.8)%, and (26.7 +/- 6.9)% respectively. When samples were divided into 2 groups according to the sensitivity of ER and PR, the apoptotic rate of 5-FU plus sandostatin was (32.2 +/- 7.9)%, in positive ER and PR group, but (20.5 +/- 5.5)% in negative ER and PR group (P < 0.05).
  
  
  CONCLUSIONS
  5-FU plus sandostatin is more sensitive in the positive ER and PR group than in the negative ER and PR group. 5-FU plus sandostatin would be helpful in the biotherapy of breast cancer patients with positive ER and PR.
authors.affiliation: Department of Surgery, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Zheng
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: B
authors.initials: B
authors.lastname: Yu
authors.forename: H
authors.initials: H
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology*; D002469:Cell Separation; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D015282:Octreotide; D005472:Fluorouracil